Stock DTC DEFENCE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Defence Therapeutics Inc.

Equities

DTC

CA24463V1013

Market Closed - Canadian Securities Exchange
Other stock markets
 03:59:05 2024-04-23 pm EDT 		5-day change 1st Jan Change
1.23 CAD -3.91% Intraday chart for Defence Therapeutics Inc. -21.66% -47.21%
Mar. 26 Defence Therapeutics Inc. Announces the Successful Testing of Second-Generation Anti-Cancer Vaccine, Called ARM-002TM CI
Mar. 01 Defence Therapeutics Inc. Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation
NE
DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION
EQ
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth
NE
DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH
EQ
Defence Therapeutics Announces Warrant Terms Amendment
NE
ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION
EQ
Defence Therapeutics Inc. Announces the Successful Testing of Second-Generation Anti-Cancer Vaccine, Called ARM-002TM
CI
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine
NE
DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
EQ
Defence Completes 2nd Tranche of Financing
NE
Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology
NE
DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
EQ
Defence Therapeutics Inc. Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update
CI
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update
NE
Defence Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Defence Therapeutics Completes 1st Tranche of Financing
NE
Defence Financing
NE
Defence Begins Trading on the OTCQB and Arranges Financing
NE
Defence Therapeutics Inc. announced that it expects to receive CAD 2.79 million in funding
CI
Defence Therapeutics Inc. Tests a New Formulation of its ACCUM-002TM Dimer CDCA-SV40 Commonly Named AccuTOX®
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DTC Stock
  4. News Defence Therapeutics Inc.